Apatinib-pegylated liposomal doxorubicin combo ups survival in ovarian cancer
07 May 2021
byAudrey Abella
The addition of the oral, small-molecule tyrosine kinase inhibitor apatinib to pegylated liposomal doxorubicin (PLD) led to a significant improvement in progression-free survival (PFS) among women with platinum-resistant or refractory recurrent ovarian cancer* compared with PLD alone, according to the results of the APPROVE trial presented at SGO 2021.